Development of biorefining pipelines (laminarin, fucoidan, ulvan) has been completed by the partners in the cooperating projects SeaMark and Marikat-BCOM. Both projects are based on the BlueBio project Marikat and expanded upon.
Laminarin size-distribution and branching patterns differently impacted DC maturation and T-cell activation, with potential applications as therapeutic agents for inflammatory diseases or vaccine enhancement.
The enzymatically produced fucoidan products resulting from treatment with this enzyme were shown to have an anti-inflammatory effect in vitro on dendritic cells co-cultured with allogeneic CD4+ T-cells. These results imply that the fucoidan oligomer products resulting from the cold enzymatic treatment of the gently extracted and purified fucoidan from S. latissima seaweed should be tested further as new anti-inflammatory biomolecules treating chronic inflammatory diseases.
The observed bioactivity trend for ulvan is interesting in the context of anti-cancer properties where promotion of Th1 cells that subsequently activates cytotoxic CD8+ T cells (effective at recognizing/destroying cancerous cells) is of grest interest.
More specifically, in this BlueBio, Knowledge Sharing, Dissemination & Communication efforts a number of special issues (representing potential obstacles for commercialization) have been addressed: Need for updated Standards. Need for re-visited Regulatory. Need for Open Access culture collections -to also cover marine fungi, algae (micro and macro), and marine bacteria
Furthermore, specific efforts have been made for ensuring that the BlueBio is also included in Microbiome overview papers (the Bluebio being an essential player in the global One Health.
Coorinator:
Gudmundur Hreggvidsson, Matis